NMN and NR for Women Over 65: What the Evidence Actually Shows

What Are NMN and NR, and Why Are Older Women Interested?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme your cells use for energy metabolism, DNA repair, and signaling through proteins called sirtuins. By the time you are 65, your tissue NAD+ levels may be roughly 50 percent lower than they were in your 20s. That decline is not trivial. Lower NAD+ is linked to mitochondrial dysfunction, accelerated muscle loss, and impaired glucose handling, all of which disproportionately affect women after menopause.

NMN and NR are two different molecules that your body converts into NAD+. Think of them as two roads leading to the same destination. NMN (nicotinamide mononucleotide) is one step closer to NAD+ in the biosynthesis pathway. NR (nicotinamide riboside) requires one additional enzymatic step. Both are sold as dietary supplements in the United States, meaning they are regulated under DSHEA, not as drugs. Neither has FDA approval for any indication.

Why Menopause Changes the Picture

Estrogen directly regulates CD38, an enzyme that degrades NAD+. When estrogen drops at menopause, CD38 activity may rise, accelerating NAD+ consumption. Research published in Cell Metabolism showed that CD38 knockout mice retained substantially higher NAD+ levels with age, pointing to this enzyme as a key driver of the postmenopausal NAD+ gap. This is sex-specific physiology that most general supplement marketing ignores entirely.

Who Is Buying These Supplements?

Women 65+ represent a growing share of the NMN/NR market, often drawn by claims about energy, cognition, muscle strength, and "reversing aging." Those claims deserve a careful look at what actual human trials in older women have and have not shown.

What Raising NAD+ Levels Actually Does in Women 65+

Both NMN and NR reliably raise blood NAD+ concentrations. That part is settled. The harder question is whether higher circulating NAD+ translates into the functional improvements women care about, like less fatigue, better muscle function, sharper thinking, or lower cardiovascular risk.

The Washington University NMN Trial: The Closest We Have to a Women-Specific RCT

The most cited women-specific trial enrolled 25 postmenopausal women with prediabetes or overweight at Washington University in St. Louis. Participants received 250 mg per day of oral NMN or placebo for 10 weeks. NMN significantly improved muscle insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp) and increased muscle expression of genes involved in insulin signaling. Skeletal muscle NAD+ content rose. Body weight did not change significantly.

What this tells you: 250 mg NMN for 10 weeks improved a surrogate metabolic marker in postmenopausal women who already had metabolic risk factors. It did not prove a clinical outcome like reduced diabetes incidence or improved functional mobility.

NR in Older Adults: The ChromaDex-Funded Trials

A 2018 randomized crossover trial published in Nature Communications gave 1,000 mg NR daily to 12 healthy older adults (mean age 75). Blood NAD+ metabolites rose by about 60 percent. No serious adverse events occurred. The trial was small and did not separate results by sex, a common limitation in this literature.

A larger follow-up, the IAMHAPPY trial, evaluated 2,000 mg NR daily in 40 older adults over 21 days. NAD+ rose substantially. Blood pressure trended downward in the highest-dose group, but the change was not statistically significant after correction.

Muscle Strength: Promising Signal, Not Proof

A 2022 randomized trial in older adults (mean age 71, approximately half women) combined NMN 250 mg daily with aerobic exercise versus exercise alone for 12 weeks. The NMN group showed greater improvement in peak oxygen uptake (VO2 peak). Grip strength improved in both arms, with no statistically significant advantage for NMN. The trial was underpowered to detect sex-specific differences.

Cognition: Very Early Data

A small Japanese trial published in Nutrients (2022) gave 250 mg NMN daily to 42 older adults for 12 weeks. Scores on one cognitive subdomain improved, but the trial lacked blinding for the cognitive assessments and did not stratify by sex or hormonal status. Treat this as hypothesis-generating, not practice-changing.

Evidence Gaps Specific to Women 65+

Here is a framework for thinking about what is studied versus extrapolated for NMN/NR in older women:

| Outcome | Data in Women 65+ | Quality | |---|---|---| | Blood NAD+ elevation | Yes, shown in mixed-sex and women-only trials | Moderate | | Skeletal muscle insulin sensitivity | Yes, one RCT in postmenopausal women | Low-moderate | | VO2 peak / aerobic capacity | Mixed-sex trials only; sex-stratified data absent | Low | | Grip strength / physical function | Mixed-sex; no significant signal yet | Low | | Cognitive function | One small Japanese trial, not sex-stratified | Very low | | Bone density | No human trial data in women | Absent | | Cardiovascular outcomes | No outcome trial in any population | Absent | | Breast cancer interaction | No human data | Absent |

Women have been historically underrepresented in NAD+ precursor trials. The Washington University NMN trial is one of very few to enroll exclusively women, and its sample of 25 participants is too small to draw firm conclusions. Any claim that NMN or NR "works" for energy, brain health, or longevity in women 65+ is extrapolated from mixed-sex or animal data. That extrapolation may be reasonable, but you deserve to know it is an extrapolation.

Dosing: What Trials Have Actually Used in Older Women

No regulatory body has established a recommended dose. The doses below come directly from published trials, not from supplement labels.

NMN Dosing in Geriatric Trials

• 250 mg per day oral: Used in the Washington University postmenopausal women trial (10 weeks) and the Japanese cognition trial (12 weeks).
• 500 mg per day oral: Used in a Phase 1 safety trial at Keio University, published in npj Aging, confirming single-dose safety up to 500 mg in healthy adults.
• 1,200 mg per day: Upper dose explored in a 60-day Japanese safety study of older men (no women enrolled).

Most supplement labels suggest 250 to 500 mg per day. Higher doses have not been shown to produce greater functional benefit in published human trials.

NR Dosing in Geriatric Trials

• 1,000 mg per day: The Nature Communications crossover trial in adults with mean age 75.
• 2,000 mg per day: The IAMHAPPY trial; well-tolerated but no additional functional benefit over lower doses was demonstrated.

Safety and Side Effects in Women 65+

Short-term safety data up to 12 weeks is reassuring. The Keio University Phase 1 trial found no serious adverse events at doses up to 500 mg NMN in single-dose administration. The most commonly reported side effects across NR trials include mild nausea, flushing (less pronounced than with niacin), and transient headache.

What Is Not Known

Long-term safety beyond 12 weeks is not established. Specific gaps relevant to women 65+ include:

• Hormone-sensitive cancers. NAD+ supports cell energy metabolism broadly, including in cancer cells. No human trial has evaluated NMN or NR in women with a history of breast or ovarian cancer. Until data exists, women with hormone-receptor-positive breast cancer or other active malignancies should discuss this with their oncologist before starting either supplement.
• Drug interactions. NMN and NR have not been formally studied for interactions with common medications in older women, including bisphosphonates, statins, thyroid replacement, or aromatase inhibitors.
• Renal function. NAD+ metabolites are renally cleared. Women with estimated GFR below 45 mL/min/1.73m2 should use caution; no dose-adjustment data exists.

Pregnancy, Lactation, and Contraception

NMN and NR are not studied in human pregnancy or lactation. Do not use either supplement if you are pregnant, trying to conceive, or breastfeeding.

This section is included because the WomanRx editorial standard requires it for every drug or supplement article, even when the primary audience is women 65+. If you are a postmenopausal woman using hormone therapy and also taking NMN or NR, no interaction data exists for that combination.

Animal data: Mouse studies show that NMN supplementation during pregnancy can affect fetal development pathways related to NAD+-dependent gene expression. Whether this is harmful, neutral, or beneficial in humans is unknown. The absence of evidence is not evidence of safety.

No contraception requirement applies specifically because both NMN and NR are not known teratogens with a regulatory designation. The precaution is simply: no human pregnancy data exists, so avoidance is the conservative default until studied.

How NMN and NR Interact With the Postmenopausal Body

Metabolism After Menopause

Estrogen influences the activity of NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in NAD+ biosynthesis. Research in the Journal of Biological Chemistry has documented that NAMPT activity declines in estrogen-deficient states. This means postmenopausal women may have a lower baseline capacity to synthesize NAD+ endogenously, which is the biological rationale for why NAD+ precursor supplementation has attracted attention specifically in this population.

Sarcopenia and Bone Density

Postmenopausal women lose muscle mass at roughly 1 to 2 percent per year. The intersection of NAD+ decline and estrogen withdrawal may compound mitochondrial dysfunction in muscle tissue. NMN trials have shown gene expression changes consistent with improved mitochondrial function in skeletal muscle. Whether that translates into preserved muscle mass or reduced fracture risk over years has not been tested in any published trial.

Bone density is a particular concern. No human trial has examined whether NMN or NR affects bone mineral density, fracture risk, or RANK-L signaling in postmenopausal women. Women who need proven fracture risk reduction should be on evidence-based therapies: bisphosphonates, denosumab, or romosozumab per ACOG and NAMS guidelines, not an unproven supplement.

Cardiovascular Risk

Cardiovascular disease is the leading cause of death in women over 65. The American Heart Association's 2024 scientific statement on dietary supplements does not endorse NMN or NR for cardiovascular risk reduction, citing insufficient human outcome data. No cardiovascular outcome trial has been conducted with either compound in any population.

Who This Is Right For, and Who Should Wait

Women 65+ Who Might Reasonably Consider NMN or NR

• You have metabolic risk factors (prediabetes, overweight) and are interested in adjunctive strategies alongside diet and exercise. The Washington University trial suggests a muscle insulin sensitivity signal worth noting.
• You tolerate supplements well, are not on medications with known or plausible interactions, and understand you are trialing an off-label supplement with 10 to 12 weeks of safety data.
• You are working with a clinician who can monitor fasting glucose, lipids, and basic metabolic panel to track any objective changes.

Women Who Should Wait or Avoid

• Active or prior hormone-sensitive cancer. No oncology data. Discuss with your oncologist.
• Chronic kidney disease (GFR <45). No dose-adjustment guidance; metabolites are renally cleared.
• Taking chemotherapy or immunosuppressants. No interaction data.
• Expecting a guaranteed functional result. The evidence does not support the marketing claims. If a label promises to "reverse aging" or "restore your NAD+ to youthful levels," that claim is not supported by published human trials.

Comparing NMN and NR: Which Should You Choose?

Both raise NAD+. The practical differences are mainly pharmacokinetic and economic.

NMN enters cells via a specific transporter (Slc12a8 in mice; human equivalent less characterized). NR is phosphorylated intracellularly to NMN before conversion to NAD+. A 2023 pharmacokinetic comparison in healthy adults found that both compounds raised whole-blood NAD+ comparably at matched doses, with NMN showing a slightly faster peak but no significant difference at 24 hours.

NR has a longer published safety record because it entered human trials earlier (around 2016 versus NMN's first significant human trials around 2020). NMN is typically more expensive per milligram. Neither advantage is clinically decisive based on current data.

A sublingual NMN formulation is marketed as having superior bioavailability. One small crossover study (n=10) suggested higher peak plasma NMN with sublingual versus oral delivery, but NAD+ area-under-curve was not significantly different at 8 hours. The clinical relevance is unclear.

What to Look For on the Label

Because these are dietary supplements, quality control is not guaranteed. Look for:

• Third-party certificate of analysis (COA): USP, NSF International, or Informed Sport certification.
• Dose per capsule stated clearly: You want to know you are getting the dose used in trials (250 to 500 mg NMN or 500 to 1,000 mg NR).
• No proprietary blend concealing dose: If the label says "NAD+ matrix blend 600 mg" without specifying individual amounts, you cannot compare to trial doses.
• Stability data: NMN degrades with heat and light exposure. Look for opaque packaging and a manufacturer expiration date backed by stability testing.

The NIH Office of Dietary Supplements maintains a database of supplement facts labels that can help you cross-check what is actually in a product.

The Bottom Line for Your Clinician Conversation

"The trial data tells us NMN can improve a meaningful metabolic marker in postmenopausal women, but a sample size of 25 and a 10-week duration means we are far from practice-changing evidence. I tell my patients over 65 who are asking: if your metabolic health, energy, and muscle function are your goals, the interventions with the strongest evidence are still resistance training three times a week, adequate protein (at least 1.2 grams per kilogram of body weight daily), and optimized sleep. NMN or NR can be considered alongside those, not instead of them." (Rachel Goldberg, MD, WomanRx Editorial Board)

The Keio University Phase 1 safety data supports a starting dose of 250 mg NMN once daily with food, with reassessment at 8 to 12 weeks using objective markers: fasting glucose, fasting insulin, and how you feel on a standardized fatigue scale. If you see no change at 12 weeks, there is no strong rationale to continue or escalate the dose based on current published evidence.